Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
2.280
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. ADR
< Previous
1
2
3
4
5
6
7
8
Next >
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
August 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
August 01, 2022
Good morning, trader! We're starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch!
Via
InvestorPlace
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
August 01, 2022
Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00...
Via
Benzinga
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
August 01, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
July 28, 2022
From
Innate Pharma SA
Via
Business Wire
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
July 21, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
June 23, 2022
From
Innate Pharma SA
Via
Business Wire
67 Biggest Movers From Yesterday
June 22, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
Via
Benzinga
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
June 03, 2022
From
Innate Pharma S.A.
Via
Business Wire
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Outcome of Innate Pharma’s 2022 Annual General Meeting
May 20, 2022
From
Innate Pharma S.A.
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
May 11, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
70 Biggest Movers From Friday
May 02, 2022
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...
Via
Benzinga
48 Stocks Moving In Friday's Mid-Day Session
April 29, 2022
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
28 Stocks Moving in Friday's Pre-Market Session
April 29, 2022
Gainers Zymeworks Inc. (NASDAQ: ZYME) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per...
Via
Benzinga
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
April 29, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
April 08, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
April 05, 2022
From
Innate Pharma SA
Via
Business Wire
Earnings Scheduled For March 24, 2022
March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to...
Via
Benzinga
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
March 24, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma FY 2021 Earnings Conference Call On March 24, 2022 At 09:00 AM ET
March 22, 2022
Innate Pharma (NASDAQ:IPHA) will host a conference call at 09:00 AM ET on March 24, 2022, to discuss FY 2021 earnings results. How to Attend Innate Pharma (IPHA) Conference Call...
Via
Benzinga
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
March 17, 2022
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 10, 2022
Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 07, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.